Novartis reported $3.4B in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US USD 3.3B 174M
Alcon AG ALC:SW USD 762M 48M
Amgen AMGN:US USD 1.29B 40M
AstraZeneca AZN:LN USD 3.35B 280M
Bayer BAYN:GR EUR 4.08B 393M
Biogen BIIB:US USD 563.3M 9.3M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Eli Lilly And LLY:US USD 1.61B 10.9M
Fresenius FRE:GR EUR 1.61B 21M
Fresenius Medical Care FME:GR EUR 990M 21M
Galapagos GLPG:NA EUR 55.51M 16.16M
Genmab GEN:DC DKK 670M 37M
Gilead Sciences GILD:US USD 1.21B 144M
GlaxoSmithKline GSK:LN GBP 1.97B 13M
Hikma Pharmaceutical HIK:LN USD 256M 0
Johnson & Johnson JNJ:US USD 6.51B 423M
Merck MRK:GR EUR 1.55B 26M
Merk MRK:US USD 2.47B 13M
Novartis NOVN:VX USD 3.4B 185M
Novartis NVS:US USD 3.4B 185M
Orion ORNBV:FH EUR 76.2M 11.5M
Pfizer PFE:US USD 3.54B 345M
Philips PHIA:NA EUR 1.33B 72M
Recordati REC:IM EUR 144.95M 131K
Regeneron Pharmaceuticals REGN:US USD 529.1M 52.8M
Roche Holding ROG:VX 5.64B 899M